Selexipag for the treatment of pulmonary arterial hypertension

O. Sitbon, R. Channick, K.M. Chin, A. Frey, S. Gaine, N. Galiè, H.-A. Ghofrani, M.M. Hoeper, I.M. Lang, R. Preiss, L.J. Rubin, L. Di Scala, V. Tapson, I. Adzerikho, J. Liu, O. Moiseeva, X. Zeng, G. Simonneau, V.V. McLaughlin, GRIPHON InvestigatorsNeville Berkman

Research output: Contribution to journalArticlepeer-review

645 Scopus citations


Background: In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension. Methods: In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patients with pulmonary arterial hypertension to receive placebo or selexipag in individualized doses (maximum dose, 1600 μg twice daily). Patients were eligible for enrollment if they were not receiving treatment for pulmonary arterial hypertension or if they were receiving a stable dose of an endothelin-receptor antagonist, a phosphodiesterase type 5 inhibitor, or both. The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of the treatment period (defined for each patient as 7 days after the date of the last intake of selexipag or placebo). Results: A primary end-point event occurred in 397 patients - 41.6% of those in the placebo group and 27.0% of those in the selexipag group (hazard ratio in the selexipag group as compared with the placebo group, 0.60; 99% confidence interval, 0.46 to 0.78; P
Original languageEnglish
Pages (from-to)2522-2533
Number of pages12
JournalNew England Journal of Medicine
Issue number26
StatePublished - 2015

Bibliographical note

cited By 567


  • endothelin receptor antagonist
  • hemoglobin
  • phosphodiesterase V inhibitor
  • placebo
  • prostanoid
  • selexipag
  • acetamide derivative
  • prodrug
  • pyrazine derivative
  • 6 minute walk distance
  • adult
  • anemia
  • arthralgia
  • Article
  • balloon atrial septostomy
  • bleeding
  • cause of death
  • controlled study
  • coughing
  • diarrhea
  • disease course
  • dizziness
  • double blind procedure
  • drug dose increase
  • drug dose reduction
  • drug efficacy
  • drug safety
  • drug withdrawal
  • dyspnea
  • endovascular surgery
  • faintness
  • fatigue
  • female
  • headache
  • heart right ventricle failure
  • hemoglobin blood level
  • hospitalization
  • hot flush
  • human
  • hyperthyroidism
  • hypotension
  • jaw pain
  • limb pain
  • long term care
  • low drug dose
  • lung transplantation
  • major clinical study
  • male
  • mortality
  • myalgia
  • nausea
  • oxygen therapy
  • peripheral edema
  • phase 4 clinical trial
  • priority journal
  • pulmonary hypertension
  • randomized controlled trial
  • rhinopharyngitis
  • upper respiratory tract infection
  • vomiting
  • walking speed
  • world health organization
  • aged
  • clinical trial
  • complication
  • drug administration
  • Hypertension
  • Pulmonary
  • Kaplan Meier method
  • middle aged
  • multicenter study
  • phase 3 clinical trial
  • statistics and numerical data
  • Acetamides
  • Aged
  • Disease Progression
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Hospitalization
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Prodrugs
  • Pyrazines


Dive into the research topics of 'Selexipag for the treatment of pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this